Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Nantahala Capital Management LLC boosted its position in Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) by 82.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 464,367 shares of the company's stock after purchasing an additional 209,367 shares during the period. Nantahala Capital Management LLC owned about 2.15% of Aileron Therapeutics worth $1,286,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in ALRN. University of Texas Texas AM Investment Management Co. purchased a new position in Aileron Therapeutics in the second quarter valued at about $4,925,000. Warberg Asset Management LLC purchased a new position in Aileron Therapeutics in the second quarter valued at about $86,000. Finally, Texas Capital Bank Wealth Management Services Inc increased its holdings in Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company's stock valued at $174,000 after buying an additional 10,398 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company's stock.

Aileron Therapeutics Price Performance

Aileron Therapeutics stock traded up $0.08 during mid-day trading on Tuesday, reaching $3.62. The company had a trading volume of 14,952 shares, compared to its average volume of 74,339. Aileron Therapeutics, Inc. has a 1 year low of $1.01 and a 1 year high of $7.42. The company has a market capitalization of $78.25 million, a P/E ratio of -1.13 and a beta of 2.33. The stock's 50-day simple moving average is $2.59 and its 200-day simple moving average is $3.57.

Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.20). On average, equities analysts forecast that Aileron Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).